Ultragenyx Pharmaceutical
RARE
163 hedge funds and large institutions have $2.01B invested in Ultragenyx Pharmaceutical in 2017 Q4 according to their latest regulatory filings, with 30 funds opening new positions, 58 increasing their positions, 47 reducing their positions, and 21 closing their positions.
43% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 21
23% more repeat investments, than reductions
Existing positions increased: 58 | Existing positions reduced: 47
5.93% more ownership
Funds ownership: 95.61% → 101.54% (+5.9%)
6% more funds holding
Funds holding: 154 → 163 (+9)
7% less capital invested
Capital invested by funds: $2.16B → $2.01B (-$158M)
38% less call options, than puts
Call options by funds: $5.25M | Put options by funds: $8.42M
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
+$43.9M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$42.8M |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$34.8M |
| 4 |
Capital International Investors
Los Angeles,
California
|
+$33.5M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$24.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
-$27.3M |
| 2 |
RFS
Rockefeller Financial Services
New York
|
-$19.5M |
| 3 |
Jennison Associates
New York
|
-$18M |
| 4 |
O
OppenheimerFunds
New York
|
-$17.7M |
| 5 |
CI
Capital International
Los Angeles,
California
|
-$10M |
RARE Hedge Fund Activity: Q4 2017 in Review
163 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Ultragenyx Pharmaceutical (RARE) for Q4 2017, worth a combined $2.01B — down 7.3% from $2.16B a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new RARE positions and 21 closed out — a net gain of 9 holders — while 58 added to existing stakes and 47 trimmed.
The largest buyer was Capital Research Global Investors, adding an estimated $43.9M. The largest seller was Eagle Asset Management, exiting entirely with an estimated $27.3M sold.
- 163 institutional investors held Ultragenyx Pharmaceutical (RARE) as of Q4 2017, up from 154 in Q3 2017.
- Funds reported $2.01B of Ultragenyx Pharmaceutical stock for Q4 2017, down 7.3% quarter-over-quarter.
- 30 funds opened new Ultragenyx Pharmaceutical positions in Q4 2017 and 21 closed out, a net change of +9 holders.
- The largest Ultragenyx Pharmaceutical buyer in Q4 2017 was Capital Research Global Investors, an estimated $43.9M added.
- The largest Ultragenyx Pharmaceutical seller in Q4 2017 was Eagle Asset Management, an estimated $27.3M sold.
Based on aggregated 13F filings for Q4 2017.